What PharmAla Biotech does

PharmAla Biotech Holdings Inc. is a Toronto-headquartered, publicly listed (CSE:MDMA, OTCQB:MDXXF) clinical-stage biotechnology company that manufactures and distributes clinical-grade MDMA drug product and develops next-generation MDXX-class novel chemical entities. Its core commercial asset is LaNeo MDMA, a GMP-manufactured encapsulated MDMA drug product offered in 20mg and 40mg strengths, which is supplied to academic medical centers, hospital systems, and government research sponsors across Canada, the United States, the Netherlands, Norway, Israel, Australia, and New Zealand. Revenue is generated through direct quote-based sales to licensed clinical research customers, supplemented by royalties and license fees from a 50/50 Australian joint venture (Cortexa, with Vitura Health) and from licensing transactions, including a May 2026 term sheet granting Jupiter Neurosciences exclusive U.S. rights to ALA-002 in a deal valued at over US$100M. A drugs-for-data supply model (Merhavim, Spaulding, Nautilus Sanctuary, Orygen) trades clinical trial material at no charge or discount in exchange for full data licensing rights, building a proprietary evidence portfolio across PTSD, fibromyalgia, social anxiety, MDD, schizophrenia, BPD, and narcissism.

The company's pipeline rests on two patented drug candidates: ALA-002, a non-racemic MDMA formulation with FDA Novel Chemical Entity recognition and engineered improvements to cardiovascular safety and reduced abuse liability (now in GMP manufacturing for Phase 2a/2b development); and APA-01, a novel non-controlled-substance MDXX molecule protected by U.S. Patent 12,042,478 with applications in post-stroke neurorehabilitation and traumatic brain injury, advanced through the Restora Neurosciences SPV. Discovery is supported by Phenesafe AI, an in-house drug discovery platform combining QSAR modeling (co-developed with the University of Windsor) with AI chemical pathway modeling, focused on identifying and patenting novel substituted phenethylamines. Commercial infrastructure includes the NEXUS Prescriber/Clinic Portal for Health Canada's Special Access Program, exclusive distribution partners in the Netherlands and New Zealand, an unnamed US third-party pharmaceutical logistics partner fully onboarded September 2025, and the wholly-owned Australian subsidiary PharmAla Biotech Australia Pty Ltd. (formed September 2025). The company is not yet profitable, with Q2 FY2026 net loss of CAD $337,696 (down 58% YoY), and is dependent on capital markets and license economics to fund pipeline development.

Name

PharmAla Biotech

Legal name

PharmAla Biotech Holdings Inc.

Website

https://pharmala.ca

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

PharmAla Biotech is a Toronto-based, publicly listed (CSE:MDMA) clinical-stage biotechnology company that manufactures and supplies GMP clinical-grade LaNeo MDMA drug product and develops next-generation MDXX-class novel chemical entities for global clinical researchers, hospitals, and government trial sponsors.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Clinical-grade MDMA
• GMP drug manufacturing
• MDXX drug discovery
• Psychedelic clinical supply
• Novel chemical entities

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Others

Revenue model

1. Clinical-Grade MDMA Drug Product Sales: One-time/transaction sales of LaNeo MDMA encapsulated capsules (20mg and 40mg) to licensed researchers, clinical trials, hospitals, and SAP prescribers in Canada, US, Netherlands, Norway, Israel, Australia, and New Zealand; subject to import/export permits and controlled-substance licensing.
2. Joint Venture Royalty Stream (Cortexa): Royalty provisions from the 50/50 Cortexa JV with Vitura Health supplying GMP MDMA into the Australian Authorised Prescriber market; includes completed three-year license at A$250,000/year plus ongoing royalty rights.
3. ALA-002 U.S. Licensing (Jupiter Neurosciences): US$3.33M upfront (US$1.5M cash + US$1.83M Jupiter stock) plus development milestone payments and single-digit royalties on net sales from exclusive U.S. license of ALA-002; total potential value >US$100M.
4. APA-01 Out-Licensing via Restora SPV: US$500,000 license fee upon Funding Threshold (US$2.5M) plus perpetual 3% royalty on net sales from Restora Neurosciences; PharmAla retains 50% founding equity with 25% anti-dilution floor.
5. Drugs-for-Data Supply Agreements: Supply of clinical trial material at no charge or discount in exchange for full data license rights (e.g., Merhavim Mental Health Centre, Spaulding Rehabilitation, Nautilus Sanctuary, Orygen), enabling commercial and regulatory use of generated clinical data.
6. Customer Deposits (Deferred Revenue): Approximately 50% of contract value received upfront as customer deposits pending issuance of clinical trial and/or import permits; Q2 2026 deposits grew by $310,719; year-end 2025 deposits stood at $276k.

Pricing tiers

Go-to-market motion1 record

Distribution channels7 records

Marketing channels8 records

Core offering

PharmAla Biotech is a Canadian biotechnology company that develops, manufactures, and supplies clinical-grade LaNeo™ MDMA encapsulated drug product (20mg and 40mg capsules) to licensed clinical researchers, hospitals, and government-sponsored trial programs, while also developing a pipeline of patented Novel Chemical Entities (NCEs) in the MDXX class — including ALA-002 (FDA-recognized NCE) and APA-01 — through proprietary AI-driven drug discovery (Phenesafe.AI) and partnered development vehicles.

Product overview

PharmAla Biotech operates a vertically integrated pharmaceutical platform centered on clinical-grade MDMA drug products and a pipeline of next-generation MDXX-class molecules. The core commercial asset is LaNeo MDMA (available in 40mg and newly introduced 20mg capsules), a GMP-manufactured MDMA drug product that serves as the revenue-generating engine and which is being supplied into Health Canada's Special Access Program, Australian commercial markets (via the Cortexa JV with Vitura Health), U.S. government-sponsored clinical trials (VA and DHA), and academic/clinical research globally. Building on LaNeo, the company is developing a next-generation pipeline: ALA-002 (a patented, FDA-recognized Novel Chemical Entity with improved cardiovascular safety, partnered via a US$100M+ U.S. licensing term sheet with Jupiter Neurosciences) and APA-01 (a patented non-controlled MDXX molecule for Traumatic Brain Injury and Post-Stroke Neurorehabilitation, advanced through the Restora Neurosciences SPV). Underpinning the R&D effort is Phenesafe.AI, a proprietary AI drug discovery platform combining QSAR modeling (co-developed with the University of Windsor) with AI chemical pathway modelling to identify and patent novel substituted phenethylamines. On the commercial side, PharmAla operates the NEXUS Portal (and its predecessor the Prescriber's Portal) to connect prescribers, therapists, and clinic managers in the MDMA-assisted therapy ecosystem. Together, these assets form a multi-product platform spanning API manufacturing, finished drug product, AI-driven discovery, and clinical/patient-access infrastructure.

Differentiator

Problem solved

Functional benefit

Brands

• LaNeo: PharmAla's clinical-grade MDMA drug product line encapsulated under GMP conditions, available in 20mg and 40mg capsule dosage forms; the only commercially available MDMA drug product approved by the US FDA for clinical trial use.
• Phenesafe AI
• NEXUS

Products and services

• LaNeo MDMA capsules Clinical-grade LaNeo MDMA encapsulated under Good Manufacturing Practice (GMP) conditions, available in 40mg capsules (and newly introduced 20mg capsules). The only commercially available MDMA drug product for clinical trial use sourced from North America. Sold to clinical trial sponsors, hospitals, and SAP prescribers in Canada, US, Netherlands, Norway, Israel, Australia, and New Zealand subject to controlled-substance licensing.
• LaNeo MDMA 20mg capsules Newly introduced 20mg clinical drug product dose of LaNeo MDMA providing additional dosing flexibility for clinical trial practitioners and clinicians treating patients with MDMA-Assisted Therapy. First supplied into the Department of Defense-funded STRONG STAR trial in active-duty military with PTSD.
• ALA-002 Patented, non-racemic MDMA formulation recognized by the U.S. FDA as a Novel Chemical Entity (NCE). Engineered with materially improved cardiovascular safety and reduced abuse liability versus racemic MDMA, while preserving pro-social and therapeutic properties. Currently in GMP manufacturing for Phase 2a/2b clinical development with Social Anxiety Disorder as the targeted 2026 indication. Subject to exclusive U.S. licensing transaction valued at over US$100M with Jupiter Neurosciences.
• APA-01 (PharmAla-1 / P-1) APA-01 is (R)-2-[(2H-1,3-benzodioxol-5-yl)methyl]pyrrolidine, a novel non-controlled MDXX-class molecule protected by United States Patent No. 12,042,478. Therapeutic applications include post-stroke neurorehabilitation and traumatic brain injury (TBI). Not classified as a controlled substance in Canada or the United States. Licensed to Restora Neurosciences SPV for IND-enabling development.

Quantifiable outcome

• Q2 2026 revenue of $220,584, up 51% YoY from $145,657
• +6 more outcomes

Named customers25 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered flagship, core and minor.

• Jupiter Neurosciences, Inc. (NASDAQ: JUNS)flagshipOEM/ Whitelabel/ Licensing Partner · 20 May 2026Term sheet (May 20, 2026) for exclusive, perpetual U.S. licensing rights to ALA-002 (PharmAla's lead next-generation non-racemic MDMA NCE). Total transaction value >US$100M, including US$3.33M upfront at closing (US$1.5M cash + US$1.83M Jupiter common stock), development milestones, and single-digit royalties on net sales. PharmAla retains all rights to ALA-002 outside the U.S. Jupiter deposits US$600,000 in escrow upon signing; closing expected within 90 days.
• Restora Neurosciences (SPV with Aluvaris Inc. & Diteba Inc.)flagshipStrategic or Co-development Partner · 13 May 2026Definitive SPV Formation, Shareholder and License Agreement (May 13, 2026) with Aluvaris Inc. (capital partner) and Diteba Inc. (anchor laboratory) for clinical/regulatory development of APA-01 (novel non-controlled MDXX molecule covered by U.S. Patent 12,042,478) targeting Post-Stroke Neurorehabilitation and Traumatic Brain Injury. PharmAla and Aluvaris each hold 50% founding equity (with PharmAla anti-dilution floor at 25%). Funding threshold US$2.5M; upon achievement, PharmAla receives US$500K license fee plus perpetual 3% royalty on net sales. IND filing targeted within 36 months.
• Diteba Inc.coreImplementation/ SI/ Consulting Partner · 13 May 2026Headquartered in Mississauga, Ontario; appointed as Restora's principal bioanalytical and scientific project management services provider for APA-01 IND development. Health Canada Drug Establishment license, FDA registration, EMA recognition, controlled-substance handling license; provides GMP/GLP-compliant analytical, bioanalytical, formulation, stability, and release testing services. Services Agreement at closing with capital-efficient fee structure and right of first offer.
• Matthew AzrieliminorOthers · 10 February 2026Advisory agreement signed February 6, 2025; includes up to 1 million Performance Share Units tied to corporate goals in media advisory, market development, and investment advisory categories. Mr. Azrieli is a current shareholder.
• Dr. Kiyan AfzaliminorOthers · 1 October 2025Appointed to the board of PharmAla Biotech Australia Pty Ltd. effective October 1, 2025. PhD from The University of Sydney; expertise in small drug-like molecules, oxytocin receptor therapeutics, neuropsychiatric disorders; co-founded Kinoxis Therapeutics and led $282M private investment rounds.
• Veridion GroupcoreChannel Partner/ Reseller/ Distributor · 25 September 2025Exclusive distribution agreement signed September 25, 2025 for the New Zealand market. Re-export restrictions; first-year annual purchase minimum waived. PharmAla anticipates shipping from existing Australian inventory allocation. Driven by Medsafe's first Authorized Prescriber approval for Psilocybin and clinician interest in MDMA.
• University of WindsorminorStrategic or Co-development Partner · 15 May 2025Collaboration partner for QSAR model development as part of Phenesafe AI drug discovery platform, originally funded by Ontario Centres of Innovation grant. Joint scientific work with Dr. James W. Gauld and Sedat Karabulut on phenethylamine structure-activity relationships.
• Unnamed US Pharmaceutical Logistics/Distribution PartnercoreChannel Partner/ Reseller/ Distributor · 24 March 2025Third-party logistics company specializing in pharmaceutical products contracted March 24, 2025; fully onboarded by September 8, 2025. Provides GMP-compliant warehousing and directed distribution of LaNeo MDMA to US clinical trial customers. Non-exclusive, no sales provision; partner acts only on PharmAla's behalf for storage and directed distribution. Mitigates US-Canada cross-border tariff and trade risk.
• Duchefa Farma B.V.coreChannel Partner/ Reseller/ Distributor · 10 March 2025Exclusive distribution agreement signed March 10, 2025 for the Netherlands market. Duchefa acts as exclusive distribution agent and Importer of Record with Qualified Person release capability. Annual purchase minimums with escalator provisions tied to regulatory changes allowing MDMA in healthcare system; restrictions on re-export and price controls.
• Cortexa (Vitura Health Limited JV)flagshipStrategic or Co-development Partner · 1 July 202350/50 joint venture with ASX-listed Vitura Health (ASX: VIT) for the Australian Authorised Prescriber market — the only legal commercial MDMA market globally. Three-year license at A$250,000/year concluded in FY2026; royalty provisions continue. Cortexa completed world's first Australian GMP MDMA capsule batch and exceeded A$1M in sales in FY2026. PharmAla holds right of first refusal on new Australian-market innovations.

Scale indicators14 records

Recent moves7 records

Expansion highlights8 records

Direct peers

• Lykos Therapeutics (formerly MAPS Public Benefit Corporation): Direct MDMA-assisted therapy developer; ran the Phase III MAPP1/MAPP2 trials that pioneered clinical MDMA research. Most direct competitor to PharmAla's LaNeo MDMA on the therapy side and competes for the same researcher and patient ecosystems.
• Mind Medicine (MindMed) Inc. Clinical-stage psychedelic medicine biotech (NASDAQ: MNMD) developing LSD and MDMA-class therapies for anxiety, ADHD, and other indications. Directly comparable as a publicly-listed psychedelic drug developer with similar regulatory and clinical milestones.
• GH Research PLC: Clinical-stage psychedelic therapeutics company (NASDAQ: GHRS) developing mebufotenin (5-MeO-DMT) therapy for treatment-resistant depression. Comparable as a publicly-listed developer of novel psychoactive compounds with similar GMP manufacturing needs.
• Compass Pathways plc: Publicly-listed mental health care company (NASDAQ: CMPS) developing psilocybin therapy for treatment-resistant depression. Comparable as a psychedelic drug developer with GMP manufacturing, clinical trial supply, and regulatory pathway challenges analogous to PharmAla's MDMA program.
• Cybin Inc. Publicly-listed (NYSE AMERICAN: CYBN) clinical-stage psychedelic company developing deuterated psilocybin analogues (CYB003) and other psychedelic-based therapeutics for depression and addiction. Directly comparable as a publicly-listed next-generation psychedelic molecule developer with analogous AI / patent strategy.
• Filament Health Corp. Publicly-listed (Cboe Canada: FH) naturally-derived psychedelic drug developer. Listed in PharmAla's affiliated partners; develops GMP botanical psilocybin drug products and competes in the clinical trial supply market.
• Numinus Wellness Inc. Publicly-listed (TSX: NUMI) mental health company operating psychedelic-assisted therapy clinics and psychedelic drug research. Listed in PharmAla's affiliated partners; provides direct competition on both drug product and clinic / prescriber-network axes.

Broad incumbents

• ATAI Life Sciences N.V. Largest publicly-listed psychedelic mental health platform (NASDAQ: ATAI), holding multiple psychedelic drug developers across psilocybin, DMT, MDMA, and ibogaine. Broad incumbent in the same psychedelic therapeutic category as PharmAla.

Regional players

• Vitura Health Limited: ASX-listed (ASX: VIT) Australian health and wellness company and PharmAla's 50/50 Cortexa JV partner. Comparable as a regional psychedelic medicines distributor in the only legal commercial MDMA market globally.

Others

• Multidisciplinary Association for Psychedelic Studies (MAPS): Non-profit research and educational organization that historically hosted PharmAla's Investigator's Brochure on its website and ran the foundational MDMA clinical trial program. Adjacent ecosystem participant rather than a direct competitor; relevant as the scientific anchor of the broader MDMA-assisted therapy field.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/jobs/view/4297157884
• Xx.com/PharmAlaBiotech
• Facebookfacebook.com/PharmAlaBiotech

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries3 records

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmAla Biotech